Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats
| dc.contributor.author | de Souza, Aline | |
| dc.contributor.author | Scarim, Cauê Benito [UNESP] | |
| dc.contributor.author | Cotrim, Paulo Cesar | |
| dc.contributor.author | Junior, Fernando Barbosa | |
| dc.contributor.author | Rocha, Bruno Alves | |
| dc.contributor.author | Calixto, Leandro Augusto | |
| dc.contributor.author | Correia, Cristiano Jesus | |
| dc.contributor.author | de Barros Araújo, Gabriel Lima | |
| dc.contributor.author | Löbenberg, Raimar | |
| dc.contributor.author | Bou-Chacra, Nádia Araci | |
| dc.contributor.author | Breithaupt-Faloppa, Ana Cristina | |
| dc.contributor.institution | Universidade de São Paulo (USP) | |
| dc.contributor.institution | Universidade Estadual Paulista (UNESP) | |
| dc.contributor.institution | Faculty of Pharmacy & Pharmaceutical Sciences | |
| dc.date.accessioned | 2025-04-29T19:34:08Z | |
| dc.date.issued | 2024-02-01 | |
| dc.description.abstract | Background: Leishmaniasis, caused by the protozoan Leishmania sp., infects phagocyte cells present in lymphatic organs. This study demonstrates the influence of nanostructured lipid carrier-loaded hydroxymethylnitrofurazone (NLC-NFOH) on lymphatic uptake using a chylomicron-blocking flow model in rats. Method: Lymphatic uptake of NFOH was assessed 1 h after oral administration of dimethyl sulfoxide with NFOH or NLC-NFOH with and without cycloheximide pretreatment. Result: Dimethyl sulfoxide with NFOH and NLC-NFOH showed NFOH serum concentrations of 0.0316 and 0.0291 μg/ml, respectively. After chylomicron blocking, NFOH was not detected. Conclusion: Despite log P below 5, NFOH was successfully taken up by the lymphatic system. Long-chain fatty acids and particle size might be main factors in these findings. NLC-NFOH is a promising and convenient platform for treating leishmaniasis via oral administration. | en |
| dc.description.affiliation | Faculty of Pharmaceutical Sciences University of São Paulo, SP | |
| dc.description.affiliation | Department of Drugs & Medicines School of Pharmaceutical Sciences São Paulo State University | |
| dc.description.affiliation | Seroepidemiology Cellular & Molecular Immunology Laboratory Institute of Tropical Medicine University of São Paulo, Dr. Enéas de Carvalho Aguiar 470, Jardim América, SP | |
| dc.description.affiliation | Laboratory of Toxicology & Essentiality of Metals Faculty of Pharmaceutical Sciences of Ribeirão Preto University of São Paulo, SP | |
| dc.description.affiliation | Federal University of São Paulo Department of Pharmaceutical Sciences Institute of Environmental Chemical & Pharmaceutical Sciences, SP | |
| dc.description.affiliation | Laboratório de Cirurgia Cardiovascular e Fisiopatologia da Circulação (LIM-11) Instituto do Coração (InCor) Faculdade de Medicina Universidade de São Paulo | |
| dc.description.affiliation | University of Alberta Faculty of Pharmacy & Pharmaceutical Sciences | |
| dc.description.affiliationUnesp | Department of Drugs & Medicines School of Pharmaceutical Sciences São Paulo State University | |
| dc.description.sponsorship | Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) | |
| dc.description.sponsorshipId | FAPESP: 2017/08332-3 | |
| dc.format.extent | 293-301 | |
| dc.identifier | http://dx.doi.org/10.2217/nnm-2023-0263 | |
| dc.identifier.citation | Nanomedicine, v. 19, n. 4, p. 293-301, 2024. | |
| dc.identifier.doi | 10.2217/nnm-2023-0263 | |
| dc.identifier.issn | 1748-6963 | |
| dc.identifier.issn | 1743-5889 | |
| dc.identifier.scopus | 2-s2.0-85186626773 | |
| dc.identifier.uri | https://hdl.handle.net/11449/304183 | |
| dc.language.iso | eng | |
| dc.relation.ispartof | Nanomedicine | |
| dc.source | Scopus | |
| dc.subject | chylomicrons | |
| dc.subject | cycloheximide | |
| dc.subject | hydroxymethylnitrofurazone | |
| dc.subject | lymphatic system | |
| dc.subject | nanostructured lipid carrier | |
| dc.title | Hydroxymethylnitrofurazone lymphatic uptake with nanostructured lipid carrier after oral administration in rats | en |
| dc.type | Artigo | pt |
| dspace.entity.type | Publication | |
| relation.isOrgUnitOfPublication | 95697b0b-8977-4af6-88d5-c29c80b5ee92 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 95697b0b-8977-4af6-88d5-c29c80b5ee92 | |
| unesp.author.orcid | 0000-0003-4307-6497[1] | |
| unesp.author.orcid | 0000-0002-2540-6395[2] | |
| unesp.author.orcid | 0000-0003-2607-8837[3] | |
| unesp.author.orcid | 0000-0002-2498-0619[4] | |
| unesp.author.orcid | 0000-0001-7893-758X[5] | |
| unesp.author.orcid | 0000-0003-1776-7470[6] | |
| unesp.author.orcid | 0000-0002-1690-9951[7] | |
| unesp.author.orcid | 0000-0001-7590-3587[8] | |
| unesp.author.orcid | 0000-0002-0919-0213[9] | |
| unesp.author.orcid | 0000-0002-5271-5468[10] | |
| unesp.author.orcid | 0000-0003-0554-0674[11] | |
| unesp.campus | Universidade Estadual Paulista (UNESP), Faculdade de Ciências Farmacêuticas, Araraquara | pt |

